SALMETEROL / FLUTICASONE INHALATION POWDER (Seffalair Spiromax ®)
Clinical Indication
Asthma
Date of classification
March 2022
Grey
Not yet reviewed drugs with no traffic light recommendation so not yet approved for use in LLR.
- New medicines, devices, appliances.
- New indication of existing medicine.
- New NICE TA which has not been reviewed.
- Not been requested for review by either TAS/LPT MMC.